Clinical trials: Ovarian Sarcoma
Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
This study will recruit patients with the following cancer indications: ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, with inoperable locally advanced or metastatic solid tumours.
- Conditions
- Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer
- Trial name
- NCT07613723
- Testing
- ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Zelluna Immunotherapy AS
Malignancy, Cancer
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
This an an open-label study to define the safety profile and the maximum tolerated dose and confirm the clinical effective dose of palifosfamide-tris given intravenously in combination with etoposide and carboplatin in a wide…
- Conditions
- Malignancy, Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01242072
- Testing
- palifosfamide-tris
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Alaunos Therapeutics
Cervical Cancer, Colorectal Cancer
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing radiation therapy to the pelvis. It is not yet known whether octreotide is effective for diarrhea.
- Conditions
- Cervical Cancer, Colorectal Cancer, Diarrhea, Endometrial Cancer
- Trial name
- NCT00033605
- Testing
- octreotide acetate, radiation
- Volunteers
- 130 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of…
- Conditions
- Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Platinum-Resistant Ovarian Carcinoma
- Trial name
- NCT05691504
- Testing
- Biopsy Procedure, Biospecimen Collection, Cobimetinib
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Carcinosarcoma, Ovarian, Carcinosarcomas Uterine
Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)
Multicenter phase II study on trabectedin in patients advanced uterine and ovarian carcinosarcoma. Patients will receive trabectedin until disease progression or unacceptable toxicity.
- Trial name
- MITO 26 (NCT02993705)
- Testing
- Trabectedin
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer, Colorectal Cancer
Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer
RATIONALE: Counting the number of circulating cancer cells in samples of blood from patients with metastatic cancer may help doctors find out how much the cancer has spread.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT00898781
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Cancer, Melanoma
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of…
- Conditions
- Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT05061537
- Testing
- PF-07263689, Sasanlimab
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Ovarian Cancer, Ovarian Carcinoma
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
This is a multicenter, open-label Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of sequentially administered CD146-targeted and GPC3-targeted CAR-T cell therapy in patients with advanced relapsed or…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovarian Sarcoma, Ovarian Cancer Stage IV
- Trial name
- BAH2573-104 (NCT07067255)
- Testing
- GPC3 CD146 CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Essen Biotech
Anal Cancer, Bladder Cancer
Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer
RATIONALE: Fiber may lessen bowel side effects caused by radiation therapy. It is not yet known whether a high-fiber diet is more effective than a low-fiber diet in preventing bowel side effects caused by radiation therapy.
- Conditions
- Anal Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer
- Trial name
- NCT01170299
- Testing
- dietary intervention, laboratory biomarker analysis, gastrointestinal complications management/prevention
- Where
- United Kingdom
- Volunteers
- 177 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Fallopian Tube Cancer, Ovarian Sarcoma
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This clinical trial studies stereotactic radiosurgery using CyberKnife works in treating women with…
- Conditions
- Fallopian Tube Cancer, Ovarian Sarcoma, Ovarian Stromal Cancer, Recurrent Cervical Cancer
- Trial name
- NCT01079832
- Testing
- stereotactic radiosurgery, quality-of-life assessment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Case Comprehensive Cancer Center
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer
- Trial name
- POTENTIATE (NCT05827614)
- Testing
- BBI-355, Erlotinib, Futibatinib
- Where
- 16 sites in United States
- Volunteers
- 85 people
- Sponsor
- Boundless Bio, Inc.
Breast Cancer, Ovarian Cancer
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
This is a Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PF-07224826, as a single agent or in…
- Conditions
- Breast Cancer, Ovarian Cancer, Liposarcoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05905341
- Testing
- PF-07224826, Fulvestrant
- Sponsor
- Pfizer
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Cervical Cancer, Endometrial Cancer
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer…
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
- Trial name
- NCT00005095
- Testing
- Ca-125, screening questionnaire administration, Surgery
- Where
- United States
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Sarcoma, Melanoma
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
This is a Phase 1b, open label, multi-center study of CMB305 (sequentially administered LV305 [a dendritic cell-targeting viral vector expressing the NY-ESO-1 gene] and G305 [NY-ESO-1 recombinant protein plus GLA-SE]) in patients…
- Conditions
- Sarcoma, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer
- Trial name
- NCT02387125
- Testing
- CMB305, G100, Metronomic CPA
- Where
- 8 sites in United States
- Volunteers
- 79 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Cervical Cancer, Endometrial Cancer
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00287885
- Testing
- docetaxel
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Colorectal Cancer, Triple Negative Breast Cancer
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
The purpose of this trial is to evaluate changes in immune activity relative to baseline following treatment with Toca 511 and Toca FC in patients with solid tumors (including recurrent high grade glioma [rHGG]) or lymphoma.
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT02576665
- Testing
- Toca 511, Toca FC
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tocagen Inc.